PE20200604A1 - Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue - Google Patents

Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue

Info

Publication number
PE20200604A1
PE20200604A1 PE2019002404A PE2019002404A PE20200604A1 PE 20200604 A1 PE20200604 A1 PE 20200604A1 PE 2019002404 A PE2019002404 A PE 2019002404A PE 2019002404 A PE2019002404 A PE 2019002404A PE 20200604 A1 PE20200604 A1 PE 20200604A1
Authority
PE
Peru
Prior art keywords
inhibitors
viral replication
dengue viral
derivatives substituted
indoline derivatives
Prior art date
Application number
PE2019002404A
Other languages
English (en)
Inventor
Jean-François Bonfanti
Bart Rudolf Romanie Kesteleyn
Dorothee Alice Marie-Eve Bardiot
Arnaud Didier M Marchand
Erwin Coesemans
Jerôme Michel Claude Fortin
Guillaume Jean Maurice Mercey
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of PE20200604A1 publication Critical patent/PE20200604A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Referido a un compuesto derivado de indolina sustituido de formula (I), incluida cualquiera de sus formas estereoquimicamente isomericas; donde R1 es trifluorometilo, trifluorometoxi o cloro; R2 es hidrogeno, fluor o metoxi; R3 es hidrogeno o metoxi; A representa -(CH2)n-, en donde n es 3 o 4; -O-(CH2)n- donde n es 2 o 4; entre otros. Dicho compuesto es util para la prevencion y tratamiento de infecciones virales por dengue. Tambien se refiere composiciones farmaceuticas que contienen dichos compuestos.
PE2019002404A 2017-05-22 2018-05-18 Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue PE20200604A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17172237 2017-05-22
PCT/EP2018/063028 WO2018215315A1 (en) 2017-05-22 2018-05-18 Substituted indoline derivatives as dengue viral replication inhibitors

Publications (1)

Publication Number Publication Date
PE20200604A1 true PE20200604A1 (es) 2020-03-10

Family

ID=58745157

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019002404A PE20200604A1 (es) 2017-05-22 2018-05-18 Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue

Country Status (25)

Country Link
US (2) US11407715B2 (es)
EP (1) EP3630723B1 (es)
JP (1) JP7203764B2 (es)
KR (1) KR102625988B1 (es)
CN (1) CN110691773B (es)
AR (1) AR111878A1 (es)
AU (1) AU2018274100B2 (es)
BR (1) BR112019024195A2 (es)
CA (1) CA3060583C (es)
CL (1) CL2019003294A1 (es)
CO (1) CO2019012035A2 (es)
CR (1) CR20190530A (es)
EA (1) EA201992782A1 (es)
EC (1) ECSP19083640A (es)
ES (1) ES2929667T3 (es)
IL (1) IL270726B2 (es)
MA (1) MA48943A (es)
MX (1) MX2019013893A (es)
NI (1) NI201900119A (es)
PE (1) PE20200604A1 (es)
PH (1) PH12019502559A1 (es)
TW (1) TWI758480B (es)
UA (1) UA125407C2 (es)
UY (1) UY37742A (es)
WO (1) WO2018215315A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
WO2017167950A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201892200A1 (ru) 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112019024311A2 (pt) 2017-05-22 2020-07-28 Janssen Pharmaceuticals, Inc. derivados de indolina substituídos como inibidores da replicação viral do dengue

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1039911B1 (en) 1997-10-27 2005-05-25 Eli Lilly And Company MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA 2 INHIBITORS
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
JP2005520795A (ja) 2001-12-12 2005-07-14 コンフォーマ・セラピューティクス・コーポレイション Hsp90阻害活性を有するプリン類似体
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
US20060211698A1 (en) 2005-01-14 2006-09-21 Genelabs, Inc. Bicyclic heteroaryl derivatives for treating viruses
US20060194835A1 (en) 2005-02-09 2006-08-31 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
MX338530B (es) 2008-06-03 2016-04-21 Siga Technologies Inc Inhibidores de molecula pequeña para el tratamiento o prevencion de infeccion de virus del dengue.
WO2010021878A1 (en) 2008-08-19 2010-02-25 Janssen Pharmaceutica Nv Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
EP2393359A4 (en) 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US7948798B1 (en) 2009-07-22 2011-05-24 Marvell International Ltd. Mixed multi-level cell and single level cell storage device
EP2523951B1 (en) 2010-01-15 2015-04-22 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
EP2552211A4 (en) 2010-03-26 2013-10-23 Glaxo Group Ltd INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
WO2013044516A1 (zh) * 2011-09-30 2013-04-04 华为技术有限公司 网络拨号的方法及装置
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
ES2655518T3 (es) 2013-10-23 2018-02-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
RS57659B1 (sr) 2014-01-31 2018-11-30 Bristol Myers Squibb Co Makrociklusi sa heterocikličnim p2' grupama kao inhibitori faktora xia
WO2016050841A1 (en) 2014-10-01 2016-04-07 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
RS58394B1 (sr) 2014-10-01 2019-04-30 Janssen Pharmaceuticals Inc Mono- ili di-supstituisani indoli kao inhibitori replikacije denga virusa
NO2721243T3 (es) 2014-10-01 2018-10-20
JOP20150335B1 (ar) 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP6864001B2 (ja) 2015-11-03 2021-04-21 ゾエティス・サービシーズ・エルエルシー ゾル−ゲルポリマー組成物及びそれらの使用
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
DK3436444T3 (da) 2016-03-31 2020-07-27 Takeda Pharmaceuticals Co Heterocyklisk forbindelse
WO2017167950A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) * 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
IL296966A (en) 2016-04-01 2022-12-01 Amgen Inc Chimeric flt-3 receptors and methods of using them
ES2930058T3 (es) 2016-04-01 2022-12-05 Kite Pharma Inc Receptores quiméricos y métodos de uso de los mismos
WO2017173206A1 (en) 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
PL3436457T3 (pl) 2016-04-01 2022-11-28 Basf Se Związki bicykliczne
EA201892200A1 (ru) 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112019024311A2 (pt) 2017-05-22 2020-07-28 Janssen Pharmaceuticals, Inc. derivados de indolina substituídos como inibidores da replicação viral do dengue

Also Published As

Publication number Publication date
IL270726B2 (en) 2023-05-01
EA201992782A1 (ru) 2020-03-24
UA125407C2 (uk) 2022-03-02
NI201900119A (es) 2020-03-23
KR102625988B1 (ko) 2024-01-16
PH12019502559A1 (en) 2021-01-25
CN110691773B (zh) 2023-06-23
CO2019012035A2 (es) 2020-01-17
US11407715B2 (en) 2022-08-09
ES2929667T3 (es) 2022-11-30
MX2019013893A (es) 2020-01-20
AU2018274100A1 (en) 2019-11-21
IL270726A (en) 2020-01-30
US11795149B2 (en) 2023-10-24
US20220340522A1 (en) 2022-10-27
JP7203764B2 (ja) 2023-01-13
CA3060583A1 (en) 2018-11-29
BR112019024195A2 (pt) 2020-06-23
IL270726B1 (en) 2023-01-01
TW201908291A (zh) 2019-03-01
US20200255376A1 (en) 2020-08-13
TWI758480B (zh) 2022-03-21
WO2018215315A1 (en) 2018-11-29
CL2019003294A1 (es) 2020-03-20
ECSP19083640A (es) 2019-11-30
CN110691773A (zh) 2020-01-14
MA48943A (fr) 2021-04-28
UY37742A (es) 2018-11-30
EP3630723A1 (en) 2020-04-08
AR111878A1 (es) 2019-08-28
CR20190530A (es) 2020-01-24
CA3060583C (en) 2024-06-04
KR20200009027A (ko) 2020-01-29
EP3630723B1 (en) 2022-08-24
AU2018274100B2 (en) 2022-06-23
JP2020520946A (ja) 2020-07-16

Similar Documents

Publication Publication Date Title
PE20200604A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
PE20200342A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
CO2020001879A2 (es) Compuesto heterocíclico y su uso
PE20180022A1 (es) Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composicion farmaceutica que comprende los mismos
CO2018004124A2 (es) Compuestos heterocíclicos
CL2018003504A1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos.
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
CL2018003105A1 (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos.
CO2017008403A2 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
PE20191652A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
PE20191461A1 (es) Compuestos amida para el tratamiento del vih
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
CO2018005941A2 (es) Formas sólidas de éster etílico del ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, sus sales y un método de preparación
CL2019002019A1 (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende.
CL2017001181A1 (es) Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4(sstr4)
CL2018000007A1 (es) Compuestos inhibidores de la señalización de la vía de notch
CR20150648A (es) Derivados de nucleósido 4´-azido, 3´-desoxi-3´-fluoro sustituido
CL2018000688A1 (es) Compuestos heterociclicos que contienen bencilamina y composiciones útiles contra infección por micobacterias
UY36141A (es) Compuestos de fórmula (i), sus sales y composiciones que lo comprenden, para su uso en el tratamiento o prevención de enfermedades mediadas por el receptor cxcr2.
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
EA201790570A1 (ru) Модуляторы р2х7
CO2021001849A2 (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende
EA201790594A1 (ru) Противомикробные композиции и способы их применения
CL2020000139A1 (es) Moduladores de lxr que contienen amina o (tio)amida.